Nomura has maintained its buy call on Zydus Lifesciences with a target price of ₹1,140 per share, implying a potential upside of about 22% from the current market price of ₹934.80. The brokerage noted that the company delivered a strong second-quarter performance, beating estimates, with profit after tax coming in 34% higher on account of forex gains.
Nomura highlighted that the India business outperformed expectations, while the US revenue missed slightly. EBITDA also came in ahead of estimates, supported by operational efficiency and a favourable product mix. The brokerage remains optimistic about Zydus Lifesciences’ steady growth trajectory driven by a strong domestic franchise and improving cost controls.
At the time of the report, Zydus Lifesciences shares were trading at ₹934.80.
Disclaimer: The views and target price mentioned are those of the brokerage firm (Nomura). This article is based solely on the provided inputs and is intended for informational purposes only. No investment advice.
